(89 days)
No
The device description and performance studies focus on mechanical and material properties (self-inflating air seal, foam insert, polypropylene deflation shield) and clinical outcomes related to safety and continence restoration, with no mention of AI or ML technologies.
Yes
The device is intended to prevent the release of stool from an end colostomy, allowing flatus to be deodorized and released, which is a therapeutic function for individuals with colostomies.
No
This device is a "Continence Control Device" intended to prevent the release of stool and allow flatus to be released and deodorized from an end colostomy. It is a therapeutic device, not a diagnostic one.
No
The device description clearly outlines a physical, single-use device with components like an "Air Seal," "foam insert," and "expandable container." The 510(k) notification concerns modifications to labeling and a material change to a physical component (deflation shield). There is no mention of software as a component or function of the device.
Based on the provided information, the VITALA™ Continence Control Device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to prevent the release of stool from an end colostomy and allow flatus to be released. This is a direct interaction with the body to manage a physiological function, not to diagnose a condition or analyze a sample in vitro (outside the body).
- Device Description: The description details a mechanical device that physically interacts with a stoma to control output. It does not involve the analysis of biological samples for diagnostic purposes.
- Clinical Studies: The clinical studies focus on the safety and effectiveness of the device in managing continence and its impact on the stoma and surrounding skin. They do not involve diagnostic testing or analysis of biological markers.
- Lack of IVD Characteristics: There is no mention of analyzing blood, urine, tissue, or any other biological sample. The device's function is entirely external and mechanical in nature.
Therefore, the VITALA™ Continence Control Device falls under the category of a medical device used for managing a physical condition, not for in vitro diagnosis.
N/A
Intended Use / Indications for Use
The VITALA™ Continence Control Device is a single-use device intended to prevent the release of stool from an end colostomy while allowing any flatus from the stoma to be deodorized and released.
To be used only with a 1 ¾ in. (45 mm) or 2 ¼ in. (57 mm) ConvaTec NATURA® skin barrier. Not intended for use with ConvaTec Moldable Technology™ skin barriers.
Product codes
EZQ
Device Description
The Vitala™ Continence Control Device is a pouchless ostomy device consisting of a self-inflating Air Seal which contacts a stoma and is held against the stoma with a low pressure, allowing flatus to be deodorized and vented while retaining stool. The Air Seal contains a soft foam insert that expands to fill the Air Seal, causing the Air Seal to expand with it. As it expands, the Air Seal gently contacts the stoma and conforms to the shape of the stoma, and is held against the stoma with a low pressure. The Air Seal will re-inflate to remain in contact with the stoma if the stoma retracts or moves away from the Air Seal.
The Vitala™ Continence Control Device also includes an expandable container to collect stool during removal of the device. This single use device is designed to be used only with a 1 ½" (45mm) or 2 ¼" (57mm) ConvaTec Natura® skin barrier, and will accommodate a range of stoma diameters.
The Vitala™ Continence Control Device is indicated for individuals with end colostomies. The device is not intended for use until the abdomen and peristomal area have fully healed from bowel surgery (typically 6-12 weeks post surgery), or for use with a stoma protrusion greater than 2 cm (when lying down). The device should also not be used in individuals with end colostomies with a history of chronic liquid stool. ConvaTec Moldable Technology™ skin barriers should not be used with the Vitala™ device.
This 510(k) notification concerns modification of the labeling for the Vitala™ Continence Control Device to allow an expanded wear time of up to 12 hours per day for the device as well as expanded compatibility with ConvaTec Natura® convex products. Otherwise, the design, materials, and manufacture of the device remain unchanged from its description in 510(k) Premarket Notification K083785, except that its deflation shield is now made from polypropylene.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
stoma, end colostomy, abdomen, peristomal area
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical Study #1:
Study type: non-randomized, open-label, multi-center, multi-national clinical study
Sample size: 78 subjects were enrolled, 66 subjects wore the Vitala™ device, 45 subjects completed the study per protocol.
Key results:
Subjects rated the Vitala™ device as good or very good in its ability to restore continence (86.9%).
The rate of Adverse Events (AEs) was 0.01 per patient per day. Nausea/vomiting/diarrhea were most commonly reported (16 subjects).
Microbiology results showed no obvious or harmful changes to normal flora.
Stoma vascularity results showed no significant difference in mean oxygen saturation (SO2) values and no evidence of systematic development of hypoxic regions.
Overall, the Vitala™ device is safe and effective at restoring continence when worn up to 12 hours daily.
Clinical Study #2:
Study type: non-randomized, open-label, multi-center clinical study
Sample size: 27 subjects enrolled, 23 subjects (85.2%) completed the study.
Key results:
Subjects rated the VitalaTM device as "good" or "very good" in its ability to restore continence (64%).
The rate of Adverse Events (AEs) was 0.02 per patient per day during the Vitala™ Stage. Nausea/vomiting/diarrhea were most commonly reported (4 subjects).
Stoma vascularity results provided no evidence of any changes in stoma and peristomal skin oxygen saturation (SO2) or the development of hypoxic/hyperoxic regions.
Safety results showed no Vitala™ device related serious adverse events (SAEs) and no abnormal findings during the VitalaTM Stage.
Overall, the Vitala™ device is safe and effective at restoring continence when worn up to 12 hours with convex products.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5900 Ostomy pouch and accessories.
(a)
Identification. An ostomy pouch and accessories is a device that consists of a bag that is attached to the patient's skin by an adhesive material and that is intended for use as a receptacle for collection of fecal material or urine following an ileostomy, colostomy, or ureterostomy (a surgically created opening of the small intestine, large intestine, or the ureter on the surface of the body). This generic type of device and its accessories includes the ostomy pouch, ostomy adhesive, the disposable colostomy appliance, ostomy collector, colostomy pouch, urinary ileostomy bag, urine collecting ureterostomy bag, ostomy drainage bag with adhesive, stomal bag, ostomy protector, and the ostomy size selector, but excludes ostomy pouches which incorporate arsenic-containing compounds.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
102536 ા of 5
DEC 1 2010
510(k) SUMMARY
| Subject Device: | VITALA™ Continence Control Device |
|---|---|
| Date Prepared: | November 29, 2010 |
| Applicant: | ConvaTec Inc. |
| 200 Headquarters Park Drive | |
| Skillman, New Jersey 08558 | |
| Contact: | Charles Ryan |
| Associate Director, US Regulatory Affairs | |
| Tel: 908-904-2541 | |
| Fax: 908-904-2235 | |
| Device Trade Name: | Vitala™ Continence Control Device |
| Classification Name: | Ostomy Pouch and Accessory (ref. 21 CFR 876.5900; |
| Product Code EZQ) | |
| Device Class: | Class I |
| Predicate Device Trade Name: | Vitala™ Continence Control Device |
| Classification Name: | Ostomy Pouch and Accessory (ref. 21 CFR 876.5900; Product Code EZQ) |
| Device Class: | Class I |
| 510(k) Substantial Equivalence: | K083785 – determined substantially equivalent on |
| April 2, 2010 |
DEVICE DESCRIPTION
The Vitala™ Continence Control Device is a pouchless ostomy device consisting of a self-inflating Air Seal which contacts a stoma and is held against the stoma with a low pressure, allowing flatus to be deodorized and vented while retaining stool. The Air Seal contains a soft foam insert that expands to fill the Air Seal, causing the Air Seal to expand with it. As it expands, the Air Seal gently contacts the stoma and conforms to the
1
K102536
pg 2 of 5
shape of the stoma, and is held against the stoma with a low pressure. The Air Seal will re-inflate to remain in contact with the stoma if the stoma retracts or moves away from the Air Seal.
The Vitala™ Continence Control Device also includes an expandable container to collect stool during removal of the device. This single use device is designed to be used only with a 1 ½" (45mm) or 2 ¼" (57mm) ConvaTec Natura® skin barrier, and will accommodate a range of stoma diameters.
The Vitala™ Continence Control Device is indicated for individuals with end colostomies. The device is not intended for use until the abdomen and peristomal area have fully healed from bowel surgery (typically 6-12 weeks post surgery), or for use with a stoma protrusion greater than 2 cm (when lying down). The device should also not be used in individuals with end colostomies with a history of chronic liquid stool. ConvaTec Moldable Technology™ skin barriers should not be used with the Vitala™ device.
This 510(k) notification concerns modification of the labeling for the Vitala™ Continence Control Device to allow an expanded wear time of up to 12 hours per day for the device as well as expanded compatibility with ConvaTec Natura® convex products. Otherwise, the design, materials, and manufacture of the device remain unchanged from its description in 510(k) Premarket Notification K083785, except that its deflation shield is now made from polypropylene.
INDICATIONS FOR USE
The VITALA™ Continence Control Device is a single-use device intended to prevent the release of stool from an end colostomy while allowing any flatus from the stoma to be deodorized and released.
To be used only with a 1 ¾ in. (45 mm) or 2 ¼ in. (57 mm) ConvaTec NATURA® skin barrier. Not intended for use with ConvaTec Moldable Technology™ skin barriers.
CLINICAL SUMMARY .
ConvaTec has performed two clinical studies to assess the safety and effectiveness of the Vitala™ Continence Control Device with an extended wear time of up to 12 hours per day as well as its compatibility with ConvaTec Natura® convex products.
Clinical Study #1
A non-randomized, open-label, multi-center, multi-national (conducted in the USA and Europe) clinical study was initiated on April 17, 2009 and completed on January 16, 2010.
The planned methodology was to enroll 75 subjects with an end colostomy of at least 12 weeks duration with formed or semi-formed effluent, who had the ability to wear a size 45mm or 57mm ConvaTec Natura® skin barrier flange, and a
2
K102536
pg 3 of 5
stoma that protruded no more than 2cm at rest (supine/on the back), as well as the ability to do complete self-care.
The primary objective of this clinical study was to assess safety during 12 hours of Vitala™ device wear by measuring the frequency of adverse events (AEs) related to stoma (including gastro-intestinal (GI), stomal and surrounding skin events), microbiology profile and stomal vascularity.
Seventy-eight subjects were enrolled in this study across study centers in the USA and Europe. Thirty-three subjects (42.3%) either withdrew or were discontinued from the study while 45 subjects (57.7%) completed the study per protocol. A total of 66 subjects wore the Vitala™ device.
Subjects in general rated the Vitala™ device as good or very good in its ability to restore continence (86.9%).
Overall, the rate of AEs during the Usual Stage (where subjects used their usual pouch system) and the Vitala™ Stage was identified at 0.01 per patient per day. Nausea/vomiting/diarrhea were the most commonly reported AEs (16 subjects) followed by abdominal pain (7 subjects) and constipation (5 subjects). Most AEs were mild or moderate in nature; however, there were 27 severe or very severe AEs. of which two were possibly related to the Vitala™ device.
Microbiology results showed that baseline evaluations established the presence of normal microflora and common microbial intestinal toxins. No obvious or harmful changes to the normal flora were noted when samples obtained during the Vitala™ Stage were compared to baseline samples. No aberrant flora were noted in the samples collected for GI events.
Stoma vascularity results showed that there was no significant difference in mean oxygen saturation (SO2) values. There was also no evidence of the systematic development of hypoxic regions in subjects who completed the study.
Overall, results from this study indicate that the Vitala™ device is safe and effective at restoring continence when worn up to 12 hours daily.
Clinical Study #2
A non-randomized, open-label, multi-center clinical study was conducted in the USA. The study was initiated on February 3, 2010 and completed on April 6, 2010, with primary objective to assess the safety of the Vitala™ Continence Control Device with 45mm and 57mm sizes of ConvaTec Natura® convex products during 12 hours of daily wear. Approximately 15 subjects who had been using some form of convex products and 10 subjects who did not normally use convexity were to be enrolled in this study.
3
K102536
pg. 4 of 5
The planned methodology was to enroll subjects with an end colostomy of at least 12 weeks duration with formed or semi-formed effluent, current users of convex skin barriers or convex inserts (enrollment targeted 15 convex users and 10 nonconvex users), willingness to wear a ConvaTec Natura® convex product in 45mm or 57mm size with a stoma opening size from 13mm up to 50mm, a stoma that protruded no more than 2cm at rest (supine / lying down on the back) and an ability to do complete self-care.
Twenty-seven subjects were enrolled in this study in the USA. Fifteen subjects who were convex users at baseline and 12 subjects who were non-convex users at baseline were enrolled into the study. Twenty-three subjects (85.2%) completed the study while four subjects (14.8%) discontinued from the study.
Subjects in general rated the VitalaTM device as "good" or "very good" in its ability to restore continence (64%).
Overall, the rate of adverse events (AEs) during the Convex Stage (where subjects used ConvaTec Natura® convex products prior to use of the Vitala™ device) was 0.03 and during the Vitala™ Stage it was identified at 0.02 per patient per day. Nausea/vomiting/diarrhea were the most commonly reported AEs (4 subjects) followed by bleed/bruise (trauma) to stoma wound, constipation and loose stool (3 subjects each). Most AEs were mild or moderate in nature and there was only one very severe AE, which was not considered to be related to the study treatment.
Stoma vascularity results provided no evidence of any changes in stoma and peristomal skin oxygen saturation (SO2) or the development of hypoxic regions in the stoma and hyperoxic regions in peristomal skin as a result of wearing the Vitala™ device with convex products.
Safety results showed no Vitala™ device related serious adverse events (SAEs) and no abnormal findings during the VitalaTM Stage. Stoma vascularity results provided no evidence of any changes in stoma and peristomal skin SO2 or the development of hypoxic regions in the stoma and hyperoxic regions in peristomal skin as a result of wearing the Vitala™ device with convex products.
Overall, results from this study indicate that the Vitala™ device is safe and effective at restoring continence when worn up to 12 hours with convex products.
OVERALL CONCLUSION
There are no significant differences in the intended use between the subject and predicate Vitala™ Continence Control Devices. The Vitala™ device is non-invasive to the stoma, and has demonstrated substantial equivalence as well as safety and effectiveness through use in clinical studies, microbiology studies, and vascularity testing of the stoma. The design, materials, and manufacture of the device remain unchanged from how it was
4
K102536
pg 5 of 5
described in 510(k) Premarket Notification K083785, except that its Deflation Shield is now made from polypropylene.
Based on the evidence provided, we propose that Vitala™ Continence Control Device can be used safely and effectively for individuals with end colostomies to prevent the release of stool from an end colostomy, for a wear time of up to twelve hours per day as well as with ConvaTec Natura® convex products.
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Mr. Charles Ryan Associate Director, U.S. Regulatory Affairs ConvaTec. Inc. 200 Headquarters Park Drive SKILLMAN NJ 08558 ·
DEC 1 2010
Re: K102536
Trade/Device Name: VITALA Continence Control Device Regulation Number: 21 CFR 8876.5900 Regulation Name: Ostomy pouch and accessories Regulatory Class: I Product Code: EZQ Dated: September 1, 2010 Received: September 3, 2010
Dear Mr. Ryan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related
6
Page 2
adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Hukert Lemur MD
Herbert P. Lerner, M.D., Director (Acting) Division of Reproductive, Gastro-Renal and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
Indications For Use
510(k) Number (if known): Not Yet Assigned
DEC 1 2010
Device Name: VITALA™ Continence Control Device
Indications For Use:
The VITALA™ Continence Control Device is a single-use device intended to prevent the release of stool from an end colostomy while allowing any flatus from the stoma to be deodorized and released.
To be used only with a 1 ¾ in. (45 mm) or 2 ¼ in. (57 mm) ConvaTec NATURA® skin barrier. Not intended for use with ConvaTec Moldable Technology™ skin barriers.
Prescription Use (21 CFR 801 Subpart D) AND/OR
Over the Counter Use XX (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off)
Division of Reproductive, Gastro-Renal, and
| Urological Devices | |
|---|---|
| 510(k) Number | K102536 |
Page 1 of _______ConvaTec Inc.
.
:
: